ArticleFrontiers in pharmacology2026
Predictive modelling of the dynamics of antimicrobial resistance: creation of a bank of renewable models based on machine learning.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The growth in antimicrobial resistance (AMR) presents a global threat, caused to a large extent by irrational antimicrobial consumption. For its part, mathematical modelling of the dynamics of AMR on the basis of data on antimicrobial consumption and historical levels of resistance may prove a promising tool for optimizing strategies to control this problem. Methods: We used data on the consumption of systemic antimicrobials in the period 2008-22 for 82 regions of the Russian Federation and AMR levels in the period 2013-22. The data was processed with standardization of the regional names, the exclusion of antimicrobials with insignificant usage, the calculation of moving averages for AMR (with a window of 3-10 years) and antimicrobial consumption in Defined Daily Doses. To reduce dimensionality, principal component analysis was employed. On the basis of the "model pair" (microorganism-antibiotic) concept we tested machine learning algorithms: Light Gradient Boosting Machine (LightGBM), Random Forest, logistic regression, Support Vector Machines (SVMs) with linear and Gaussian kernels. We performed the calibration of the hyperparameters with cross-validation and assessed the metrics of precision and recall. We carried out predictions of AMR for optimized Constrained Optimization BY Linear Approximation (COBYLA method) and realistic Error, Trend, Seasonality (ETS model) usage scenarios. Results: For the model pair Discussion: The bank of models created on the basis of LightGBM provides for precise forecasting of the dynamics of AMR and the formation of strategies for the management of antimicrobial therapy. An optimization of consumption according to the results of the modelling is capable of reducing resistance by 15-20%. The AMCmodel.ru platform provides tools for real-time decision-making. An online platform AMCmodel.ru has been developed for data visualization, access to models and forecast generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.